INCY Incyte Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: INCY

Price (delayed)

$127.74

Market cap

$25.89B

P/E Ratio

15.73

Dividend/share

N/A

EPS

$8.12

Enterprise value

$21.94B

?
Relative Growth: Rel. Growth: 98
Relative Strength: Rel. Strength: 81
Relative Valuation: Rel. Valuation: 79
Relative Profitability: Rel. Profitability: 99

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of ...

Highlights
INCY's net income has soared by 85% year-on-year and by 13% since the previous quarter
INCY's EPS has soared by 84% YoY and by 11% QoQ
INCY's P/E is 80% below its 5-year quarterly average of 78.5 but 12% above its last 4 quarters average of 14.0
Sector: Healthcare
Industry: Biotechnology
Website: http://www.incyte.com
Peers: AMGN LGND PFE LLY

Key stats

What are the main financial stats of INCY

INCY stock price

How has the Incyte stock price performed over time
Intraday
-0.3%
1 week
0.41%
1 month
7.46%
1 year
50.57%
YTD
29.33%
QTD
12.69%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$5.82B
Gross profit
$5.39B
Operating income
$1.78B
Net income
$1.61B
Gross margin
92.6%
Net margin
27.7%
INCY's net income has soared by 85% year-on-year and by 13% since the previous quarter
Incyte's operating income has soared by 50% YoY and by 10% from the previous quarter
The net margin is up by 46% year-on-year and by 3.7% since the previous quarter
INCY's gross profit is up by 27% year-on-year and by 9% since the previous quarter

Price vs fundamentals

How does INCY's price correlate with its fundamentals

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
INCY P/E details
P/E
15.73
P/B
4.02
P/S
4.4
EV/EBIT
11.14
EV/EBITDA
10.61
EV/Sales
3.77
INCY's EPS has soared by 84% YoY and by 11% QoQ
INCY's P/E is 80% below its 5-year quarterly average of 78.5 but 12% above its last 4 quarters average of 14.0
INCY's equity has surged by 52% year-on-year and by 13% since the previous quarter
The stock's price to book (P/B) is 12% more than its 5-year quarterly average of 3.6 and 12% more than its last 4 quarters average of 3.6
Incyte's revenue has increased by 27% YoY and by 9% from the previous quarter
INCY's P/S is 19% above its last 4 quarters average of 3.7 and 10% above its 5-year quarterly average of 4.0

Efficiency

How efficient is Incyte business performance
INCY's return on assets is up by 43% year-on-year and by 4.1% since the previous quarter
The ROIC has increased by 40% YoY and by 10% from the previous quarter
The ROE has grown by 23% YoY
INCY's ROS is up by 22% YoY and by 2.1% QoQ

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
The company's quick ratio has surged by 69% YoY and by 27% QoQ
The current ratio has soared by 61% YoY and by 25% from the previous quarter
The debt is 99% smaller than the equity
INCY's equity has surged by 52% year-on-year and by 13% since the previous quarter
The debt is down by 10% year-on-year and by 3.4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.